Phenex Pharmaceuticals AG is a drug discovery and development company, focused on small-molecule therapeutics.

Latest News

Phenex collaborates with Mathias Heikenwälder ́s research group from DKFZ (German Cancer Research Center)
Phenex kooperiert mit Mathias Heikenwälders Forschungsgruppe am DKFZ (Deutsches Krebsforschungszentrum)

Upcoming Events - Meet us

Recent Poster Presentations

GS-9674 shows reduced side effect profile in mice, monkeys and human phase I studies compared to its predecessor Px-102PDF

Oral presentation: LXR inverse agonists reduce steatosis and fibrosis in the STAM mouse model but also improve insulin sensitivity in a high fat diet mouse clamp study, AbstractPDF
EASL The International Liver Congress 2019, April 10-14, Vienna, Austria
Targeting the IDO1-Kynurenine-AhR pathway for cancer immunotherapyPDF
AACR Annual Meeting 2019, March 29 - Apr 3, 2019, Atlanta, Georgia, USA
Identification of a potent, orally bioavailable and selective MCT4 inhibitor for the treatment of solid Warburg tumorsPDF
AACR Annual Meeting 2019, March 29 - Apr 3, 2019, Atlanta, Georgia, USA
Unexpected anti-diabetic effects and anti-fibrotic activities of LXR inverse agonists in mouse models of NADFLD/NASHPDF
American Association for the Study of the Liver Diseases: “The Liver Meeting™ 2018”, November 9-13, 2018 San Francisco, USA